3-iodobenzylguanidine has been researched along with Cancer, Second Primary in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Braunstein, SE; DuBois, SG; Fishel Ben Kenan, R; Haas-Kogan, DA; Hawkins, RA; Matthay, KK; Polishchuk, AL | 1 |
| Jimenez, C; Lu, Y | 1 |
| Jimenez, C; Lu, Y; Xu, G | 1 |
| Deyell, RJ; Farfan, M; Irwin, MS; Moorehead, PC; Morgenstern, DA; Portwine, C; Rafael, MS; Shammas, A; Usmani, N; Vali, R; Vanniyasingam, T | 1 |
| Clement, S; Kremer, LCM; Ronckers, CM; Teepen, J; Tytgat, L; van den Heuvel-Eibrink, MM; van Santen, HM | 1 |
| Bordbar, M; Shahriari, M; Shakibazad, N; Zareifar, S; Zekavat, OR | 1 |
| Batra, V; DuBois, SG; Fetzko, S; Huibregtse, KE; Marachelian, A; Maris, JM; Matthay, KK; Neuhaus, J; Vo, KT; Weiss, B; Yanik, GA | 1 |
| Argov, S; Lantsberg, S; Liel, Y; Zirkin, HJ; Zucker, G | 1 |
| Bertolazzi, L; De Bernardi, B; Di Cataldo, A; Gambini, C; Garaventa, A; Haupt, R; Pizzitola, MR; Villavecchia, G | 1 |
| Hawkins, RA; Huberty, J; Matthay, KK; Vora, A; Weiss, B | 1 |
| Alhava, E; Kekäläinen, P; Niskanen, L; Vanninen, E | 1 |
1 trial(s) available for 3-iodobenzylguanidine and Cancer, Second Primary
| Article | Year |
|---|---|
Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
Topics: 3-Iodobenzylguanidine; Adolescent; Adult; Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Combined Modality Therapy; Female; Hematologic Neoplasms; Humans; Infant; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Neuroblastoma; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Young Adult | 2016 |
10 other study(ies) available for 3-iodobenzylguanidine and Cancer, Second Primary
| Article | Year |
|---|---|
Anatomic patterns of relapse and progression following treatment with
Topics: 3-Iodobenzylguanidine; Disease Progression; Humans; Iodine Radioisotopes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neuroblastoma; Retrospective Studies | 2022 |
Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Aged, 80 and over; Brain Neoplasms; Humans; Male; Neoplasms, Second Primary; Paraganglioma; Peripheral Nervous System Neoplasms; Pheochromocytoma | 2023 |
Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131 I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Brain Neoplasms; Humans; Neoplasms, Second Primary; Neuroendocrine Tumors; Paraganglioma; Peripheral Nervous System Neoplasms; Pheochromocytoma | 2023 |
Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome.
Topics: 3-Iodobenzylguanidine; Guanidine; Humans; N-Myc Proto-Oncogene Protein; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neuroblastoma; Positron-Emission Tomography; Retrospective Studies | 2021 |
RE: Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with
Topics: 3-Iodobenzylguanidine; Humans; Incidence; Iodine Radioisotopes; Neoplasms, Second Primary; Neuroblastoma; Radiopharmaceuticals; Risk Factors | 2017 |
Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy.
Topics: 3-Iodobenzylguanidine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; Female; Histone Deacetylase Inhibitors; Humans; Iodine Radioisotopes; Neoplasms, Second Primary; Neuroblastoma; Panobinostat; Radiopharmaceuticals; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2020 |
Malignant pheochromocytoma simulating meningioma: coexistence of recurrent meningioma and metastatic pheochromocytoma in the base of the skull.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Antineoplastic Agents; Diagnosis, Differential; Follow-Up Studies; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pheochromocytoma; Skull Base Neoplasms; Time Factors; Tomography, X-Ray Computed | 2002 |
Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.
Topics: 3-Iodobenzylguanidine; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Hypothyroidism; Infant; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Neuroblastoma; Peripheral Nervous System Neoplasms; Radiopharmaceuticals; Survival Rate; Treatment Outcome | 2003 |
Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma.
Topics: 3-Iodobenzylguanidine; Bone Marrow; Child; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Infant; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radionuclide Imaging; Radiopharmaceuticals; Recurrence; Time Factors | 2003 |
A pitfall of metaiodobenzylguanidine scan: paraganglioma in close proximity to adrenocortical adenoma.
Topics: 3-Iodobenzylguanidine; Adenoma; Adrenal Cortex Neoplasms; Chromogranin A; Chromogranins; Humans; Magnetic Resonance Imaging; Metanephrine; Middle Aged; Neoplasms, Second Primary; Pheochromocytoma; Radionuclide Imaging; Radiopharmaceuticals | 2003 |